{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T02:43:56Z","timestamp":1788576236121,"version":"build-2803163510"},"reference-count":49,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000861","name":"Burroughs Wellcome Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000861","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["K24CA208132"],"award-info":[{"award-number":["K24CA208132"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["T32CA160040"],"award-info":[{"award-number":["T32CA160040"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011621","name":"Winship Cancer Institute of Emory University","doi-asserted-by":"publisher","award":["P30CA138292"],"award-info":[{"award-number":["P30CA138292"]}],"id":[{"id":"10.13039\/100011621","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.clml.2018.12.019","type":"journal-article","created":{"date-parts":[[2019,1,2]],"date-time":"2019-01-02T20:36:26Z","timestamp":1546461386000},"page":"300-309.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Assessing the Effectiveness of Treatment Sequences for Older Patients With High-risk Follicular Lymphoma With a Multistate Model"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9991-8457","authenticated-orcid":false,"given":"\u00c7a\u011flar","family":"\u00c7a\u011flayan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Terawaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8720-0280","authenticated-orcid":false,"given":"Turgay","family":"Ayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan S.","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiushi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Flowers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2018.12.019_bib1","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.hoc.2008.07.013","article-title":"Follicular lymphoma: clinical features and treatment","volume":"22","author":"Tan","year":"2008","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.clml.2018.12.019_bib2","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes [e-pub ahead of print]","author":"Teras","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clml.2018.12.019_bib3","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1093\/annonc\/mdx189","article-title":"Unmet needs in the first-line treatment of follicular lymphoma","volume":"28","author":"Casulo","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2018.12.019_bib4","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.12.019_bib5","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2018.12.019_bib6","doi-asserted-by":"crossref","first-page":"6624","DOI":"10.1158\/1078-0432.CCR-13-1120","article-title":"A\u00a0comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab vs CHOP\u00a0+ 131iodine-tositumomab","volume":"19","author":"Press","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2018.12.019_bib7","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2018.12.019_bib8","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1200\/JCO.1999.17.8.2499","article-title":"Low-grade stage III-IV follicular lymphoma: multivariate analysis of prognostic factors in 484 patients\u2014a study of the Groupe d'Etude des Lymphomes de l'Adulte","volume":"17","author":"Decaudin","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.12.019_bib9","first-page":"783","article-title":"Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases","volume":"95","author":"Federico","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.12.019_bib10","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1093\/annonc\/mdf198","article-title":"Age-related differences among patients with follicular lymphoma and the importance of prognostic scoring systems: analysis from a population-based non-Hodgkin\u2019s lymphoma registry","volume":"13","author":"Maartense","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2018.12.019_bib11","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the International Follicular Lymphoma Prognostic Factor Project","volume":"27","author":"Federico","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.12.019_bib12","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-Celigny","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.12.019_bib13","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/annonc\/mds429","article-title":"Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices","volume":"24","author":"Nooka","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2018.12.019_bib14","first-page":"141","article-title":"An empirical transition matrix for non-homogeneous Markov chains based on censored observations","volume":"5","author":"Aalen","year":"1978","journal-title":"Scand J Statist"},{"key":"10.1016\/j.clml.2018.12.019_bib15","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J\u00a0Am Stat Assoc"},{"key":"10.1016\/j.clml.2018.12.019_bib16","series-title":"Statistical Methods Based on Counting Processes","author":"Andersen","year":"1993"},{"key":"10.1016\/j.clml.2018.12.019_bib17","series-title":"Encyclopedia of Biostatistics","article-title":"Aalen-Johansen estimator","author":"\u00d8","year":"2005"},{"key":"10.1016\/j.clml.2018.12.019_bib18","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0167-7152(01)00155-9","article-title":"Validity of the Aalen-Johansen estimators of stage occupation probabilities and Nelson-Aalen estimators of integrated transition hazards for non-Markov models","volume":"55","author":"Datta","year":"2001","journal-title":"Stat Prob Lett"},{"key":"10.1016\/j.clml.2018.12.019_bib19","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1093\/biomet\/62.2.269","article-title":"Partial likelihood","volume":"62","author":"Cox","year":"1975","journal-title":"Biometrika"},{"key":"10.1016\/j.clml.2018.12.019_bib20","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables","volume":"34","author":"Cox","year":"1972","journal-title":"J\u00a0Roy Stat Soc B"},{"key":"10.1016\/j.clml.2018.12.019_bib21","series-title":"International Classification of Diseases for Oncology","author":"World Health Organization","year":"2013"},{"issue":"suppl","key":"10.1016\/j.clml.2018.12.019_bib22","article-title":"Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population","volume":"40","author":"Warren","year":"2002","journal-title":"Med Care"},{"key":"10.1016\/j.clml.2018.12.019_bib23","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/bjh.13399","article-title":"Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma-related mortality in elderly follicular lymphoma in the United States","volume":"170","author":"Nabhan","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.12.019_bib24","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1080\/10428194.2016.1253836","article-title":"Patterns of use and survival outcomes of positron emission tomography for initial staging in elderly follicular lymphoma patients","volume":"58","author":"Rai","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2018.12.019_bib25","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1200\/JCO.2008.18.1495","article-title":"Follicular lymphoma in the United States: first report of the national LymphoCare study","volume":"27","author":"Friedberg","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.12.019_bib26","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1365-2141.2009.08065.x","article-title":"Validation of follicular lymphoma international prognostic index 2 (FLIPI2) score in an independent series of follicular lymphoma patients","volume":"149","author":"Arcaini","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.12.019_bib27","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1200\/JCO.2016.66.9440","article-title":"Baseline metabolic tumor volume predicts outcome in high\u2013tumor-burden follicular lymphoma: a pooled analysis of three multicenter studies","volume":"34","author":"Meignan","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.12.019_bib28","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2018.12.019_bib29","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.clml.2014.12.011","article-title":"Efficacy and tolerability of anthracycline-based therapy in elderly patients with diffuse large B-cell lymphoma","volume":"15","author":"Davis","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2018.12.019_bib30","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1200\/JCO.2007.10.9710","article-title":"Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B experience","volume":"25","author":"Muss","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.12.019_bib31","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/nrclinonc.2013.158","article-title":"Drug rechallenge and treatment beyond progression\u2014implications for drug resistance","volume":"10","author":"Kuczynski","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clml.2018.12.019_bib32","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nrclinonc.2010.122","article-title":"Rechallenging with anthracyclines and taxanes in metastatic breast cancer","volume":"7","author":"Palmieri","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clml.2018.12.019_bib33","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1200\/JCO.2007.12.5070","article-title":"Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study","volume":"26","author":"Friedberg","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.12.019_bib34","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S1470-2045(16)30097-3","article-title":"Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial","volume":"17","author":"Sehn","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2018.12.019_bib35","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1200\/JCO.2014.59.9258","article-title":"Randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma: CALGB 50401 (Alliance)","volume":"33","author":"Leonard","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.12.019_bib36","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1038\/leu.2013.95","article-title":"Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial","volume":"27","author":"Wang","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.12.019_bib37","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1182\/blood-2016-06-718106","article-title":"Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103","volume":"128","author":"Ujjani","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.12.019_bib38","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2018.12.019_bib39","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1182\/blood-2016-12-757740","article-title":"Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy","volume":"129","author":"Gopal","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.12.019_bib40","doi-asserted-by":"crossref","first-page":"e156","DOI":"10.3324\/haematol.2016.151738","article-title":"Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study","volume":"102","author":"Salles","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.12.019_bib41","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte","volume":"15","author":"Brice","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.12.019_bib42","doi-asserted-by":"crossref","first-page":"6555","DOI":"10.1200\/JCO.2016.34.15_suppl.6555","article-title":"Impact of marital status on the survival of patients with hematologic malignancies reported to the California Cancer Registry","volume":"34","author":"Wieduwilt","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.12.019_bib43","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1191\/0962280202SM276ra","article-title":"Multi-state models for event history analysis","volume":"11","author":"Andersen","year":"2002","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.clml.2018.12.019_bib44","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1093\/ije\/dyr213","article-title":"Competing risks in epidemiology: possibilities and pitfalls","volume":"41","author":"Andersen","year":"2012","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.clml.2018.12.019_bib45","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.115.017719","article-title":"Introduction to the analysis of survival data in the presence of competing risks","volume":"133","author":"Austin","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.clml.2018.12.019_bib46","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1467-985X.2009.00618.x","article-title":"Breast cancer survival, competing risks and mixture cure model: a Bayesian analysis","volume":"173","author":"Basu","year":"2010","journal-title":"J\u00a0R Stat Soc Series A (Stat Soc)"},{"key":"10.1016\/j.clml.2018.12.019_bib47","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","article-title":"Estimation of failure probabilities in the presence of competing risks: new representations of old estimators","volume":"18","author":"Gooley","year":"1999","journal-title":"Stat Med"},{"key":"10.1016\/j.clml.2018.12.019_bib48","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Open-label, randomized, noninferiority study of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of advanced indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.12.019_bib49","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1200\/JCO.2016.70.8651","article-title":"Thirty-month complete response as a surrogate end point in first-line follicular lymphoma therapy: an individual patient-level analysis of multiple randomized trials","volume":"35","author":"Shi","year":"2016","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018311248?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018311248?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:32:07Z","timestamp":1761870727000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265018311248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S2152265018311248"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2018.12.019","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessing the Effectiveness of Treatment Sequences for Older Patients With High-risk Follicular Lymphoma With a Multistate Model","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2018.12.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}